Clinical Trial Listings
Formal Study Name: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Stephen Behrman, MD
Stephen Behrman, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
David Engle, MD
David Engle, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Salil Goorha, MD
Salil Goorha, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
IB/IIA
IB/IIA
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Raza, MD
Muhammad Raza, MD
Locations Where Open:
Formal Study Name: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Mirza, MD
Muhammad Mirza, MD
Locations Where Open:
Formal Study Name: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Stephen Behrman, MD
Stephen Behrman, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Salil Goorha, MD
Salil Goorha, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Salil Goorha, MD
Salil Goorha, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II/III
II/III
Trial Type:
Interventional
Interventional
Principal Investigator:
Sadanand Patil, MD
Sadanand Patil, MD
Locations Where Open:
Formal Study Name: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Aleksandar Jankov, MD
Aleksandar Jankov, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Raza, MD
Muhammad Raza, MD
Locations Where Open:
Formal Study Name: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Mirza, MD
Muhammad Mirza, MD
Locations Where Open:
Formal Study Name: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Stephen Behrman, MD
Stephen Behrman, MD
Locations Where Open:
Formal Study Name: Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Mirza, MD
Muhammad Mirza, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
N/A
N/A
Trial Type:
Observational
Observational
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
N/A
N/A
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
N/A
N/A
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: The National Myelodysplastic Syndromes (MDS) Study
Anatomic Site:
Blood and Marrow
Blood and Marrow
Histology:
Myelodysplastic Syndromes (MDS)
Myelodysplastic Syndromes (MDS)
Mutation:
Stage:
Any
Any
Treatment Phase: Patients suspected to have MDS and are undergoing diagnostic work-up with planned bone marrow assessments to confirm MDS or to evaluate disease status.
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Salil Goorha, MD
Salil Goorha, MD
Locations Where Open:
Formal Study Name: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Anatomic Site:
Breast
Breast
Histology:
HER2 Positive
HER2 Positive
Mutation:
N/A
N/A
Stage:
I, II, or III
I, II, or III
Treatment Phase: Patients with residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes per the surgical pathology report are eligible; however, patients with HR+ HER2+ cancers must have node-positive residual disease per the surgical pathology report in order to qualify for the study
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Philip Lammers
Dr. Philip Lammers
Locations Where Open:
Formal Study Name:
Anatomic Site:
Breast
Breast
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Angela H. Wortham, MD
Angela H. Wortham, MD
Locations Where Open:
Formal Study Name: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Anatomic Site:
Breast
Breast
Histology:
Any
Any
Mutation:
Hormone receptor -positive or hormone receptor- negative HER2-positive breast cancer are eligible
Hormone receptor -positive or hormone receptor- negative HER2-positive breast cancer are eligible
Stage:
II through IIIA
II through IIIA
Treatment Phase: Patient must have histologically confirmed HER2-positive primary invasive breast carcinoma
Trial Phase:
II
II
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Drew Dill
Dr. Drew Dill
Locations Where Open:
Formal Study Name:
Anatomic Site:
Breast
Breast
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III
Anatomic Site:
Breast
Breast
Histology:
Breast Carcinoma
Breast Carcinoma
Mutation:
HER2+
HER2+
Stage:
IV, Recurrent Breast Carcinoma
IV, Recurrent Breast Carcinoma
Treatment Phase: Must have metastatic breast cancer and initiating or continuing trastuzumab-based HER-2 targeted therapy without concurrent anthracyclines in first or second line setting
Trial Phase:
III
III
Trial Type:
Supportive Care
Supportive Care
Principal Investigator:
Sailendra Vasireddy, MD
Sailendra Vasireddy, MD
Locations Where Open:
Formal Study Name: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Anatomic Site:
Breast
Breast
Histology:
Any
Any
Mutation:
Stage:
Any
Any
Treatment Phase: Patients must have inflammatory breast cancer without distant metastases
Trial Phase:
II
II
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Philip Lammers
Dr. Philip Lammers
Locations Where Open:
Formal Study Name:
Anatomic Site:
Breast
Breast
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Breast
Breast
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Interventional
Interventional
Principal Investigator:
Lindi H. VanderWalde, MD
Lindi H. VanderWalde, MD
Locations Where Open:
Formal Study Name: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study
Anatomic Site:
Breast
Breast
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Colorectal
Colorectal
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II/III
II/III
Trial Type:
Interventional
Interventional
Principal Investigator:
Donald Gravenor, MD
Donald Gravenor, MD
Locations Where Open:
Formal Study Name: Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Anatomic Site:
Breast
Breast
Histology:
Mutation:
Stage:
Treatment Phase: Patients must not have previous personal history of breast cancer including ductal carcinoma in situ. Patients must be scheduled for, or have intent to schedule, a screening mammogram
Trial Phase:
III
III
Trial Type:
Screening/Interventional
Screening/Interventional
Principal Investigator:
Lynn Gayden, MD
Lynn Gayden, MD
Locations Where Open:
Formal Study Name: ADELA-CAMPERR- cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase: NA
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Histology:
Mutation:
Stage:
Treatment Phase: NA
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Osarogiagbon
Osarogiagbon
Locations Where Open:
Formal Study Name:
Anatomic Site:
Hepatobiliary
Hepatobiliary
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Mirza, MD
Muhammad Mirza, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Hepatobiliary
Hepatobiliary
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Muhammad Mirza, MD
Muhammad Mirza, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Anatomic Site:
Lung
Lung
Histology:
Advanced Nonsquamous Non-Small Cell Lung Cancer
Advanced Nonsquamous Non-Small Cell Lung Cancer
Mutation:
PD-L1 expression Tumor Proportion Score (TPS) >= 1% in tumor cells
PD-L1 expression Tumor Proportion Score (TPS) >= 1% in tumor cells
Stage:
IV; Patients with Stage IIIB and IIIC disease are eligible if they are not candidates for combined chemotherapy and radiation
IV; Patients with Stage IIIB and IIIC disease are eligible if they are not candidates for combined chemotherapy and radiation
Treatment Phase: Patients must NOT have received the following: prior systemic chemotherapy or immunotherapy
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Philip Lammers
Dr. Philip Lammers
Locations Where Open:
Formal Study Name: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Anatomic Site:
Lung
Lung
Histology:
Non-small cell lung cancer
Non-small cell lung cancer
Mutation:
Any
Any
Stage:
IIIA/B/C
IIIA/B/C
Treatment Phase: Newly diagnosed stage IIIA/B/C non-small cell lung cancer (NSCLC) (per the American Joint Committee on Cancer [AJCC] 8th edition) that is unresectable and is histologically and/or cytologically confirmed; Nodal recurrence after surgery for early stage NSCLC
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Philip Lammers
Dr. Philip Lammers
Locations Where Open:
Formal Study Name: This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC.
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice. A phase IV, prospective, single arm, multi-center, observational study to collect safety and outcome data of Zepzelca in adult participants with extensive stage SCLC previously exposed to at least one line of treatment with platinum-based chemotherapy. Patients enrolled in the study will be encouraged to complete patient reported outcome (PRO) questionnaires.
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II/III
II/III
Trial Type:
Interventional
Interventional
Principal Investigator:
Shailesh. R Satpute, MD
Shailesh. R Satpute, MD
Locations Where Open:
Formal Study Name: This research trial collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs. Tumor tissue and blood samples are procured during procedures that are required for the patients' clinical management and will be stored via xenograft (transplant to another species) models or in vitro cell culture for future analysis.
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Anatomic Site:
Lung
Lung
Histology:
Small Cell Lung Cancer
Small Cell Lung Cancer
Mutation:
Any
Any
Stage:
Extensive Stage or Limited Stage Small Cell Lung Cancer
Extensive Stage or Limited Stage Small Cell Lung Cancer
Treatment Phase: Any
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Shailesh Satpute
Dr. Shailesh Satpute
Locations Where Open:
Formal Study Name: This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name: A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Anatomic Site:
Lung
Lung
Histology:
Non-small cell lung cancer
Non-small cell lung cancer
Mutation:
Any
Any
Stage:
II or III
II or III
Treatment Phase: Participants must not be candidates for surgical resection in the opinion of the treating investigator. Participants whose disease was previously resected must have experienced local or regional recurrence at least 12 months after resection
Trial Phase:
II
II
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Kathleen Spiers
Dr. Kathleen Spiers
Locations Where Open:
Formal Study Name: cfMeDIP-seq Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name: Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: A MASTER PROTOCOL TO EVALUATE BIOMARKER-DRIVEN THERAPIES AND IMMUNOTHERAPIES IN PREVIOUSLY-TREATED NON-SMALL CELL LUNG CANCER (Lung-MAP Screening Study)
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II & III
II & III
Trial Type:
Interventional
Interventional
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name: A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
III
III
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: Screening Study for Participants With Malignant Tumors
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD
Locations Where Open:
Formal Study Name: A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
(NeoCOAST-2
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name: An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study (DiRECT)
Anatomic Site:
Lung
Lung
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
Trial Type:
Observational
Observational
Principal Investigator:
Philip Lammers, MD
Philip Lammers, MD
Locations Where Open:
Formal Study Name:
Anatomic Site:
Non-Colorectal
Non-Colorectal
Histology:
Mutation:
Stage:
Treatment Phase:
Trial Phase:
II
II
Trial Type:
Interventional
Interventional
Principal Investigator:
Aleksandar Jankov, MD
Aleksandar Jankov, MD
Locations Where Open:
Formal Study Name: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Anatomic Site:
Ovarian, Fallopian Tube, Primary Peritoneal
Ovarian, Fallopian Tube, Primary Peritoneal
Histology:
Any
Any
Mutation:
Stage:
II, III, or IV
II, III, or IV
Treatment Phase: Patients must have newly diagnosed, stage II-IV low-grade serous ovarian cancer. Ovarian cancer = ovarian, fallopian tube and primary peritoneal cancers
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. David Engle
Dr. David Engle
Locations Where Open:
Formal Study Name: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Anatomic Site:
Pancreas
Pancreas
Histology:
Any
Any
Mutation:
N/A
N/A
Stage:
Tx-4, N0-1, M0
Tx-4, N0-1, M0
Treatment Phase: Any
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Dr. Stephen Behrman
Dr. Stephen Behrman
Locations Where Open:
Formal Study Name: This is the "Formal Study Name" field
Anatomic Site:
This is the "Anatomic Site" field
This is the "Anatomic Site" field
Histology:
This is the "Histology" field
This is the "Histology" field
Mutation:
This is the "Mutation" field
This is the "Mutation" field
Stage:
This is the "Stage" field
This is the "Stage" field
Treatment Phase: This is the "Treatment Phase" field
Trial Phase:
This is the "Trial Phase" field
This is the "Trial Phase" field
Trial Type:
This is the "Trial Type" field
This is the "Trial Type" field
Principal Investigator:
This is the "PI" field
This is the "PI" field
Study Link:
This is the "Study Link" field
Locations Where Open:
Formal Study Name: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST screening trial)
Anatomic Site:
Lung
Lung
Histology:
Squamous, Non-Small Cell Lung Cancer (NSCLC), Large Cell Lung Carcinoma
Squamous, Non-Small Cell Lung Cancer (NSCLC), Large Cell Lung Carcinoma
Mutation:
Stage:
Squamous & SCLC: Stage IB, Stage IIA, Stage IIB, Stage IIIA
Squamous & SCLC: Stage IB, Stage IIA, Stage IIB, Stage IIIA
Treatment Phase: Patients with suspected diagnosis of resectable or completely resected NSCLC and have not received neoadjuvant therapy for this cancer.
Trial Phase:
Trial Type:
Screening
Screening
Principal Investigator:
Todd Robbins, MD
Todd Robbins, MD
Locations Where Open:
Formal Study Name: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Anatomic Site:
Lung
Lung
Histology:
Non-Small Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
Mutation:
Fusion
Fusion
Stage:
Carcinoma: Stage IB, Stage IIA, Stage IIB; NSCLC: Stage IIIA
Carcinoma: Stage IB, Stage IIA, Stage IIB; NSCLC: Stage IIIA
Treatment Phase: Patients have undergone complete surgical resection of their cancer and have negative margins and registered to A151216.
Trial Phase:
III
III
Trial Type:
Treatment
Treatment
Principal Investigator:
Todd Robbins, MD
Todd Robbins, MD
Locations Where Open: